Researchers compared COVID-19 outcomes in rheumatoid arthritis patients treated with biologic vs conventional DMARDs.
CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to reduce the likelihood that it will reach the dreaded "difficult-to-treat" stage ...
Nonadherence to DMARDs in RA varies widely, with rates from 1.5% to 100% across different studies and DMARD classes. The review identified 31 unique nonadherence measures, with indirect methods like ...